About Us
Exelixis is a biotechnology company focused on discovering, developing, and commercializing innovative therapies to improve the lives of patients with difficult-to-treat cancers. Founded in 1994 and headquartered in Alameda, California, Exelixis has a strong commitment to advancing cancer treatment through cutting-edge research in molecular biology and targeted drug development. The company's flagship products, including cabozantinib (marketed as CABOMETYX®), have gained recognition for their effectiveness in treating various forms of cancer, such as renal cell carcinoma and hepatocellular carcinoma. Driven by a mission to make a meaningful impact in oncology, Exelixis continues to pursue new therapeutic solutions through rigorous scientific research and strategic partnerships, aiming to address unmet needs in cancer care and provide hope for patients worldwide.